Effects of Okra on blood glucose of patients with diabetes mellitus type 2

Assessment of antidiabetic effect of Abelmoschus culentesus (Okra) on diabetes mellitus type 2 patients who received oral agents

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160310026998N8

Enrollment

128

Registered

2018-07-13

Start date

2639-04-21

Completion date

Unknown

Last updated

2018-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes mellitus type 2. E11

Interventions

Intervention 1: Intervention group: Okra capsule 750 mg, two capsule every 6 hours, 30 minutes before meal for two months. Intervention 2: Control group: placebo capsule contains cellulose 750 mg, two

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: All patients older than 18 years with diabetes mellitus type 2 who received oral agents (metformin/sulfonylureas/pioglitazone)

Exclusion criteria

Exclusion criteria: pregnancy and lactation creatinine clearance less than 30 ml/min severe hepatic impairment

Design outcomes

Primary

Measure	Time frame
Reduce the fasting blood sugar. Timepoint: At baseline and two months after intervention. Method of measurement: Blood sample analysis.;Hemoglobin a1c. Timepoint: At baseline and two months after intervention. Method of measurement: Blood sample analysis.	—

Secondary

Measure	Time frame
Reduce of low density lipoprotein (LDL). Timepoint: At baseline and two months after intervention. Method of measurement: Blood sample analysis.;Weight loss. Timepoint: At baseline and two months after intervention. Method of measurement: scale.;Reduce triglycerides. Timepoint: At baseline and two months after intervention. Method of measurement: Blood sample analysis.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaba Ghaffary

Tabriz University of Medical Sciences

ghaffarys@tbzmed.ac.ir+41 33365010

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026